NURS f6630 fMidterm fExam
Question1 1
out of 1 points f f f
When an unstable patient asks why it is necessary to add medications
f f f f f f f f f f f
to his current regimen, the PMHNP’s best response would be:
f f f f f f f f f f
Selected C. f
Answer: “Many psychiatric illnesses involve several dys-functioning neurotransmitter systems in
f f f f f f f f
f the brain. Often, a single medication may only effect one or two of the dys-functioning
f f f f f f f f f f f f f f
f systems. The addition of another medication can work with the current medication in
f f f f f f f f f f f f
f stabilizing multiple neurotransmitter systems and help to alleviate your symptoms.”
f f f f f f f f f
• Question 2 f
0 out of 1 points
f f f f
The PMHNP is meeting with a new mother who would like to begin
f f f f f f f f f f f f
taking medication again to treat her bipolar depression; she is
f f f f f f f f f f
breastfeeding her 2-month old daughter. The PMHNP recognizes
f f f f f f f f
that which of the following medications is contraindicated for this
f f f f f f f f f f
patient?
f
Selected C.
Answer:
f Lithium
(Lithobid)
f
• Question 3 f
1 out of 1 points
f f f f
Mr. Gordon is a middle-aged client who was started on antidepressant
f f f f f f f f f f
monotherapy for depression. After beginning this medication, the PMHNP
f f f f f f f f f
noticed that this client seemed to swing into a hypomanic episode. What can the
f f f f f f f f f f f f f f
PMHNP infer from this behavior change?
f f f f f f
Selected A.
Answer:
f
This client may have Bipolar III disorder
f f f f f f
• Question 4 f
1 out of 1 points
f f f f
A patient presents with frequent episodes of mania. Which statement
f f f f f f f f f
describes an appropriate treatment approach for this patient?
f f f f f f f f
Selected B.
Answer:
f “The patient could benefit from an f f f f f
, anticonvulsant.”
• Question 5 f
1 out of 1 points
f f f f
The student inquires about antipsychotic medications. Which
f f f f f f
response by the PMHNP describes the factors that contribute to
f f f f f f f f f f
reduced risk of extrapyramidal symptoms (EPS) for patients who take
f f f f f f f f f f
antipsychotics?
f
Selected B.
Answer:
f Those that are potent D2 antagonists with 5HT2A
f f f f f f f
antagonism properties
f f
• Question 6 f
1 out of 1 points f f f f
After ordering flumazenil (Rumazicon) the PMHNP cautions the staff to monitor for which
f f f f f f f f f f f f
possible effect?
f f
Selected D.
Answer:
f All of the f f
above
f
• Question 7 f
1 out of 1 points
f f f f
The PMHNP is caring for a patient who is taking antipsychotics heard
f f f f f f f f f f f
the psychiatrist tell the patient that the patient would be placed on a
f f f f f f f f f f f f f
different antipsychotic agent called an atypical antipsychotic. What
f f f f f f f f
neurotransmitters will this new medication work on?
f f f f f f f
Selected A.
Answer:
f dopamine and serotonin f f
• Question 8 f
1 out of 1 points
f f f f
While genes have potential to modify behavior, behavior can also
f f f f f f f f f
modify genes. How do genes impact this process?
f f f f f f f f
Selected B.
Answer:
f Changes made to proteins lead to changes in f f f f f f f
behavior.
f
• Question 9 f
1 out of 1 points
f f f f
Mrs. Schwartzman is a 52-year-old client with schizophrenia and no
f f f f f f f f f
established history of depression. When meeting with the PMHNP, she
f f f f f f f f f f
presents with apathy and withdrawn social behavior, and she reports a loss of
f f f f f f f f f f f f f
joy from enjoyable activities since starting her new medication. What does
f f f f f f f f f f f
, the PMHNP infer from this encounter with the client?
f f f f f f f f
Selected C.
Answer:
f The new medication is blocking D2 receptors in the mesolimbic
f f f f f f f f f
system
f
• Question 10 f
1 out of 1 points
f f f f
A nursing student is seeking clarification on the use of
f f f f f f f f f
anticonvulsants to treat depression and is unclear about most f f f f f f f f
effective outcomes. Which of the following agents does the PMHNP
f f f f f f f f f f
convey as having uncertain outcomes?
f f f f f
Selected B.
Answer:
f Gabapentin
(Neurontin)
f
• Question 11 f
1 out of 1 points
f f f f
As it relates to G-protein linked receptors, what does the PMHNP
f f f f f f f f f f
understand about medications that are used in practice?
f f f f f f f f
Selected A.
Answer:
f Most medications that act on G-protein linked
f f f f f f
receptors have antagonistic traits.
f f f f
• Question 12 f
1 out of 1 points
f f f f
A patient is seeking pharmacological treatment for smoking
f f f f f f f
cessation. Which drug class does the PMHNP prescribe to the patient?
f f f f f f f f f f f
Selected D.
Answer:
f Varenicline
(Chantix)
f
• Question 13 f
1 out of 1 points
f f f f
The PMHNP is caring for a patient with schizophrenia and is
f f f f f f f f f f
considering a variety of treatment approaches. The PHMNP selects a
f f f f f f f f f f
viable treatment that is consistent with the “dopamine hypothesis of
f f f f f f f f f f
schizophrenia.” What action does the PMHNP anticipate this
f f f f f f f f
treatment having on the patient?
f f f f f
Selected B.
Answer:
f
, Hyperactivity in the mesolimbic dopamine pathway f f f f f
mediates the positive symptoms of schizophrenia.
f f f f f f
• Question 14 f
1 out of 1 points
f f f f
Though medications have the ability to target neurotransmitter release into the
f f f f f f f f f f
synapse by the presynaptic neuron it is not always necessary. The PMHNP
f f f f f f f f f f f f
understands that this is because:
f f f f f
Selected C.
Answer:
f Neurotransmitters can spread by f f f
diffusion.
f
• Question 15 f
1 out of 1 points
f f f f
A patient is being prescribed a sedating antidepressant, but is
f f f f f f f f f
concerned about weight gain. Which medication is most likely to be
f f f f f f f f f f f
prescribed to addresses the patient’s concerns?
f f f f f f
Selected D.
Answer:
f trazadone
(Oleptro)
f
• Question 16 f
1 out of 1 points
f f f f
The PMHNP is caring for several patients who present with various
f f f f f f f f f f
symptoms and health issues. For which patient does the PMHNP
f f f f f f f f f f
prescribe pregabalin (Lyrica)?
f f f
Selected B.
Answer:
f Patient with partial f f
seizures
f
• Question 17 f
1 out of 1 points
f f f f
Which statement about neurotransmitters and medications is true?
f f f f f f f
Selected B.
Answer:
f Several psychiatric medications have been developed after discoveries of endogenous
f f f f f f f f f
neurotransmitters and defining their function in the brain.
f f f f f f f f
• Question 18 f
1 out of 1 points
f f f f
A patient is prescribed 50 mg of desvenlafaxine to take every other
f f f f f f f f f f f
day for major depressive disorder. What does the PMHNP
f f f f f f f f f
Question1 1
out of 1 points f f f
When an unstable patient asks why it is necessary to add medications
f f f f f f f f f f f
to his current regimen, the PMHNP’s best response would be:
f f f f f f f f f f
Selected C. f
Answer: “Many psychiatric illnesses involve several dys-functioning neurotransmitter systems in
f f f f f f f f
f the brain. Often, a single medication may only effect one or two of the dys-functioning
f f f f f f f f f f f f f f
f systems. The addition of another medication can work with the current medication in
f f f f f f f f f f f f
f stabilizing multiple neurotransmitter systems and help to alleviate your symptoms.”
f f f f f f f f f
• Question 2 f
0 out of 1 points
f f f f
The PMHNP is meeting with a new mother who would like to begin
f f f f f f f f f f f f
taking medication again to treat her bipolar depression; she is
f f f f f f f f f f
breastfeeding her 2-month old daughter. The PMHNP recognizes
f f f f f f f f
that which of the following medications is contraindicated for this
f f f f f f f f f f
patient?
f
Selected C.
Answer:
f Lithium
(Lithobid)
f
• Question 3 f
1 out of 1 points
f f f f
Mr. Gordon is a middle-aged client who was started on antidepressant
f f f f f f f f f f
monotherapy for depression. After beginning this medication, the PMHNP
f f f f f f f f f
noticed that this client seemed to swing into a hypomanic episode. What can the
f f f f f f f f f f f f f f
PMHNP infer from this behavior change?
f f f f f f
Selected A.
Answer:
f
This client may have Bipolar III disorder
f f f f f f
• Question 4 f
1 out of 1 points
f f f f
A patient presents with frequent episodes of mania. Which statement
f f f f f f f f f
describes an appropriate treatment approach for this patient?
f f f f f f f f
Selected B.
Answer:
f “The patient could benefit from an f f f f f
, anticonvulsant.”
• Question 5 f
1 out of 1 points
f f f f
The student inquires about antipsychotic medications. Which
f f f f f f
response by the PMHNP describes the factors that contribute to
f f f f f f f f f f
reduced risk of extrapyramidal symptoms (EPS) for patients who take
f f f f f f f f f f
antipsychotics?
f
Selected B.
Answer:
f Those that are potent D2 antagonists with 5HT2A
f f f f f f f
antagonism properties
f f
• Question 6 f
1 out of 1 points f f f f
After ordering flumazenil (Rumazicon) the PMHNP cautions the staff to monitor for which
f f f f f f f f f f f f
possible effect?
f f
Selected D.
Answer:
f All of the f f
above
f
• Question 7 f
1 out of 1 points
f f f f
The PMHNP is caring for a patient who is taking antipsychotics heard
f f f f f f f f f f f
the psychiatrist tell the patient that the patient would be placed on a
f f f f f f f f f f f f f
different antipsychotic agent called an atypical antipsychotic. What
f f f f f f f f
neurotransmitters will this new medication work on?
f f f f f f f
Selected A.
Answer:
f dopamine and serotonin f f
• Question 8 f
1 out of 1 points
f f f f
While genes have potential to modify behavior, behavior can also
f f f f f f f f f
modify genes. How do genes impact this process?
f f f f f f f f
Selected B.
Answer:
f Changes made to proteins lead to changes in f f f f f f f
behavior.
f
• Question 9 f
1 out of 1 points
f f f f
Mrs. Schwartzman is a 52-year-old client with schizophrenia and no
f f f f f f f f f
established history of depression. When meeting with the PMHNP, she
f f f f f f f f f f
presents with apathy and withdrawn social behavior, and she reports a loss of
f f f f f f f f f f f f f
joy from enjoyable activities since starting her new medication. What does
f f f f f f f f f f f
, the PMHNP infer from this encounter with the client?
f f f f f f f f
Selected C.
Answer:
f The new medication is blocking D2 receptors in the mesolimbic
f f f f f f f f f
system
f
• Question 10 f
1 out of 1 points
f f f f
A nursing student is seeking clarification on the use of
f f f f f f f f f
anticonvulsants to treat depression and is unclear about most f f f f f f f f
effective outcomes. Which of the following agents does the PMHNP
f f f f f f f f f f
convey as having uncertain outcomes?
f f f f f
Selected B.
Answer:
f Gabapentin
(Neurontin)
f
• Question 11 f
1 out of 1 points
f f f f
As it relates to G-protein linked receptors, what does the PMHNP
f f f f f f f f f f
understand about medications that are used in practice?
f f f f f f f f
Selected A.
Answer:
f Most medications that act on G-protein linked
f f f f f f
receptors have antagonistic traits.
f f f f
• Question 12 f
1 out of 1 points
f f f f
A patient is seeking pharmacological treatment for smoking
f f f f f f f
cessation. Which drug class does the PMHNP prescribe to the patient?
f f f f f f f f f f f
Selected D.
Answer:
f Varenicline
(Chantix)
f
• Question 13 f
1 out of 1 points
f f f f
The PMHNP is caring for a patient with schizophrenia and is
f f f f f f f f f f
considering a variety of treatment approaches. The PHMNP selects a
f f f f f f f f f f
viable treatment that is consistent with the “dopamine hypothesis of
f f f f f f f f f f
schizophrenia.” What action does the PMHNP anticipate this
f f f f f f f f
treatment having on the patient?
f f f f f
Selected B.
Answer:
f
, Hyperactivity in the mesolimbic dopamine pathway f f f f f
mediates the positive symptoms of schizophrenia.
f f f f f f
• Question 14 f
1 out of 1 points
f f f f
Though medications have the ability to target neurotransmitter release into the
f f f f f f f f f f
synapse by the presynaptic neuron it is not always necessary. The PMHNP
f f f f f f f f f f f f
understands that this is because:
f f f f f
Selected C.
Answer:
f Neurotransmitters can spread by f f f
diffusion.
f
• Question 15 f
1 out of 1 points
f f f f
A patient is being prescribed a sedating antidepressant, but is
f f f f f f f f f
concerned about weight gain. Which medication is most likely to be
f f f f f f f f f f f
prescribed to addresses the patient’s concerns?
f f f f f f
Selected D.
Answer:
f trazadone
(Oleptro)
f
• Question 16 f
1 out of 1 points
f f f f
The PMHNP is caring for several patients who present with various
f f f f f f f f f f
symptoms and health issues. For which patient does the PMHNP
f f f f f f f f f f
prescribe pregabalin (Lyrica)?
f f f
Selected B.
Answer:
f Patient with partial f f
seizures
f
• Question 17 f
1 out of 1 points
f f f f
Which statement about neurotransmitters and medications is true?
f f f f f f f
Selected B.
Answer:
f Several psychiatric medications have been developed after discoveries of endogenous
f f f f f f f f f
neurotransmitters and defining their function in the brain.
f f f f f f f f
• Question 18 f
1 out of 1 points
f f f f
A patient is prescribed 50 mg of desvenlafaxine to take every other
f f f f f f f f f f f
day for major depressive disorder. What does the PMHNP
f f f f f f f f f
